TriangleRoginolisib + Venetoclax + Rituximab (NCT06644183)
Roginolisib + Venetoclax + Rituximab trial for Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT06644183). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with chronic lymphocytic leukemia that has come back or not responded to treatment.
The idea: combine three drugs. Roginolisib, a new capsule that blocks PI3 kinase delta. Venetoclax, a tablet that blocks BCL-2. And rituximab, an antibody given by vein.
The study looks at safety and whether the combination works against the cancer.
This phase 1 and 2 study plans 64 patients. At Dana-Farber Cancer Institute in Boston, Jennifer Brown leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.